Clinical Trials Logo

Hyperalgesia, Secondary clinical trials

View clinical trials related to Hyperalgesia, Secondary.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03966508 Completed - Clinical trials for Hyperalgesia, Secondary

Reliability of Measuring the Area and Intensity of Secondary Hyperalgesia Induced by High Frequency Stimulation

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

This study is designed to evaluate the method of assessing the and intensity areas of secondary hyperalgesia induced by High Frequency Stimulation (HFS). Measures of the areas of secondary hyperalgesia will take place on two experimental days separated by a minimum of two weeks. Each experimental day, the areas of secondary hyperalgesia will be assessed three times, starting 30 minutes following HFS. Furthermore, the investigators will assess if anxiety, catastrophization, stress and demographic variables modulate the extend of hyperalgesia.

NCT ID: NCT01015807 Completed - Clinical trials for Hyperalgesia, Secondary

Transversus Abdominis Plane (TAP) Block for Cesarean Section

CLOTAP
Start date: November 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a transversus abdominis plane (TAP) block with Clonidine added to the injectate (Clo-TAP) performed approximately 2hrs after the cesarean section (CS) will decrease the amount of postoperative hyperalgesia and ultimately reduce post-CS chronic pain.

NCT ID: NCT00785863 Completed - Clinical trials for Hyperalgesia, Secondary

Modulation of Remifentanil-induced Postinfusion Hyperalgesia

Start date: December 2008
Phase: Phase 4
Study type: Interventional

In addition to alleviate pain there is growing evidence that µ-opioids enhance pain. This problem is known as opioid induced hyperalgesia(OIH).The NMDA receptor is involved in opioid induced hyperalgesia it may be possible to block OIH by cyclooxygenase inhibitors. This has been demonstrated with parecoxib, a COX-II inhibitor, in a experimental pain model.Both COX-1 and COX-2 are expressed in the spinal cord. It would be of interest to investigate whether a COX-1 preferring inhibitor like ketorolac also can reduce opioid induced hyperalgesic in this experimental pain model.

NCT ID: NCT00561782 Completed - Spinal Cord Injury Clinical Trials

MR Spectroscopy as a Diagnostic and Outcome Measure in Pain and SCI

MRS
Start date: October 2007
Phase: N/A
Study type: Observational

The goal of this study is to compare the changes that occur in sensation and chemical properties of the brain following SCI between individuals that experience chronic pain and those that do not, and between those with SCI and the able-bodied.